Zacks Research Issues Optimistic Forecast for BPMC Earnings

Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Research analysts at Zacks Research raised their Q1 2025 EPS estimates for Blueprint Medicines in a report issued on Wednesday, March 5th. Zacks Research analyst A. Chakraborty now forecasts that the biotechnology company will post earnings of ($0.76) per share for the quarter, up from their previous estimate of ($0.85). The consensus estimate for Blueprint Medicines' current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Blueprint Medicines' Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.50) EPS, FY2025 earnings at ($2.13) EPS, Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at $0.16 EPS, Q3 2026 earnings at $0.21 EPS and FY2026 earnings at $0.50 EPS.

BPMC has been the topic of several other research reports. HC Wainwright reiterated a "buy" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. JMP Securities reaffirmed a "market outperform" rating and issued a $125.00 price target on shares of Blueprint Medicines in a research note on Friday, February 14th. Scotiabank began coverage on Blueprint Medicines in a research report on Friday. They issued a "sector outperform" rating and a $150.00 price objective for the company. Stephens restated an "overweight" rating and issued a $140.00 target price on shares of Blueprint Medicines in a report on Thursday, January 2nd. Finally, Guggenheim reaffirmed a "buy" rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $125.21.

Remove Ads

Blueprint Medicines Price Performance

NASDAQ BPMC traded up $1.07 on Friday, reaching $87.76. 618,419 shares of the company's stock traded hands, compared to its average volume of 1,004,368. The stock has a market cap of $5.61 billion, a PE ratio of -81.26 and a beta of 0.58. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. Blueprint Medicines has a 12 month low of $80.68 and a 12 month high of $121.90. The stock has a 50-day simple moving average of $99.38 and a 200 day simple moving average of $94.16.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in BPMC. Vanguard Group Inc. lifted its holdings in Blueprint Medicines by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 6,774,884 shares of the biotechnology company's stock valued at $590,905,000 after purchasing an additional 91,450 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Blueprint Medicines by 5.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,679,089 shares of the biotechnology company's stock valued at $495,331,000 after purchasing an additional 291,822 shares during the period. Wellington Management Group LLP lifted its stake in shares of Blueprint Medicines by 8.0% during the 4th quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock valued at $373,421,000 after buying an additional 316,754 shares in the last quarter. State Street Corp boosted its holdings in Blueprint Medicines by 16.2% in the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company's stock worth $255,827,000 after buying an additional 385,818 shares during the period. Finally, William Blair Investment Management LLC increased its stake in Blueprint Medicines by 16.1% in the 4th quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company's stock worth $169,616,000 after buying an additional 269,896 shares in the last quarter.

Insider Transactions at Blueprint Medicines

In related news, insider Ariel Hurley sold 1,819 shares of the firm's stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total value of $169,639.94. Following the transaction, the insider now directly owns 14,967 shares of the company's stock, valued at approximately $1,395,822.42. This trade represents a 10.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kate Haviland sold 1,446 shares of the business's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total value of $159,407.04. Following the sale, the chief executive officer now directly owns 149,378 shares of the company's stock, valued at $16,467,430.72. This represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 48,427 shares of company stock worth $4,837,801 in the last quarter. Company insiders own 4.21% of the company's stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.